Scibase: Closing the valuation gap driven by 90% likelihood of achieving US reimbursement - Vator
Obtaining payment for medtech products from government bodies and private insurance companies is generally not a clear-cut route, and breaking into the US market is key for medtech companies to drive sales growth. Challenges is this area are common reasons why early-stage commercial medtech companies become stranded; consequently, some investors avoid these early-stage companies prior to them showing traction in the payor process. The flip side to this exact same coin is the good news; the stock market rewards medtech companies handsomely when they break through, unlock payor coverage, and deliver consecutive commercial advances translating into steady sales growth.
